SAN CARLOS, Calif.--(BUSINESS WIRE)--NuGEN Technologies, Inc., a market leader in the development of solutions for Next Generation Sequencing (NGS) applications, has announced the release of a novel targeted enrichment method that, in a single assay, will detect all possible fusion events involving 446 cancer fusion genes as curated by the Wellcome Trust Sanger Institute’s Catalog of Somatic Mutations in Cancer (COSMIC). The proprietary NuGEN technology uses a unique single primer strategy that requires only one partner exon to be targeted, thereby enabling not only detection of known fusion events but also discovery of novel gene fusions and alternative splice forms.
Hey, check out all the research scientist jobs. Post your resume today!
